Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_4
2
29%
Ph not_applicable
1
14%
Ph phase_1
3
43%
Ph phase_2
1
14%

Phase Distribution

3

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
3(42.9%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 4Post-market surveillance
2(28.6%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(1)
Other(1)

Detailed Status

Completed5
unknown1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (42.9%)
Phase 21 (14.3%)
Phase 42 (28.6%)
N/A1 (14.3%)

Trials by Status

unknown114%
terminated114%
completed571%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_1

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

NCT04827134
terminatedphase_4

Dolutegravir in Reservoirs

NCT02924389
completedphase_1

Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet

NCT02569346
completedphase_2

Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).

NCT02868580
completedphase_4

SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

NCT02509195
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT04827134Phase 1

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

Completed
NCT02924389Phase 4

Dolutegravir in Reservoirs

Terminated
NCT02569346Phase 1

Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet

Completed
NCT02868580Phase 2

Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).

Completed
NCT02509195Phase 4

SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over

Completed
NCT02556268Phase 1

Interaction With HIV Antiretroviral Agents

Completed
NCT03275701Not Applicable

Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC

Unknown

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7